No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NBIXNeurocrine Biosciences, Inc. | 13.49B | 135.33 | 41.13 | 24.81% | 15.95% | 14.25% | 4.13% | 0.18 |
| SUPNSupernus Pharmaceuticals, Inc. | 2.97B | 51.80 | 39.24 | 8.94% | -2.8% | -1.82% | 5.76% | 0.03 |
| PTPIPetros Pharmaceuticals, Inc. | 338.98K | 0.01 | -0.00 | -12.2% | -9.68% | -208.53% | ||
| QNTMQuantum BioPharma Ltd. | 26.94M | 7.01 | -0.56 | -379.78% | 0.08 | |||
| AYTUAytu BioPharma, Inc. | 28.02M | 2.75 | -1.27 | 1.84% | -20.52% | -56.41% | 1.21 | |
| AQSTAquestive Therapeutics, Inc. | 429.45M | 3.52 | -6.90 | 13.8% | -158.95% | |||
| AVDLAvadel Pharmaceuticals plc | 2.11B | 21.50 | -42.16 | 5.05% | -0.11% | -0.28% | 0.02 | |
| RGCRegencell Bioscience Holdings Limited | 17.39B | 35.17 | -4042.53 | -67.02% | 0.01 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 14.05M | 15.58M | 9.56M | 7.81M | 5.99M | 5.82M | 5.11M |
| Revenue Growth % | - | 0.11% | -0.39% | -0.18% | -0.23% | -0.03% | -0.12% |
| Cost of Goods Sold | 10.48M | 12.72M | 4.05M | 1.6M | 2.29M | 1.63M | 1.21M |
| COGS % of Revenue | 0.75% | 0.82% | 0.42% | 0.2% | 0.38% | 0.28% | 0.24% |
| Gross Profit | 3.57M | 2.86M | 5.51M | 6.21M | 3.7M | 4.19M | 3.9M |
| Gross Margin % | 0.25% | 0.18% | 0.58% | 0.8% | 0.62% | 0.72% | 0.76% |
| Gross Profit Growth % | - | -0.2% | 0.93% | 0.13% | -0.4% | 0.13% | -0.07% |
| Operating Expenses | 11.22M | 25.02M | 22.8M | 24.26M | 23.62M | 17.81M | 21.58M |
| OpEx % of Revenue | 0.8% | 1.61% | 2.38% | 3.11% | 3.94% | 3.06% | 4.22% |
| Selling, General & Admin | 11.22M | 19.73M | 15.67M | 15.59M | 12.21M | 9.26M | 8.75M |
| SG&A % of Revenue | 0.8% | 1.27% | 1.64% | 2% | 2.04% | 1.59% | 1.71% |
| Research & Development | 0 | 0 | 459.64K | 1.79M | 1.74M | 2.41M | 2.62M |
| R&D % of Revenue | - | - | 0.05% | 0.23% | 0.29% | 0.41% | 0.51% |
| Other Operating Expenses | 0 | 5.29M | 6.66M | 6.88M | 9.67M | 6.14M | 10.21M |
| Operating Income | -7.65M | -19.31M | -17.28M | -18.05M | -19.92M | -13.62M | -17.68M |
| Operating Margin % | -0.54% | -1.24% | -1.81% | -2.31% | -3.32% | -2.34% | -3.46% |
| Operating Income Growth % | - | -1.52% | 0.11% | -0.04% | -0.1% | 0.32% | -0.3% |
| EBITDA | 414.72K | -14.02M | -10.53M | -11.17M | -14.2M | -10.2M | -14.74M |
| EBITDA Margin % | 0.03% | -0.9% | -1.1% | -1.43% | -2.37% | -1.75% | -2.88% |
| EBITDA Growth % | - | -34.81% | 0.25% | -0.06% | -0.27% | 0.28% | -0.44% |
| D&A (Non-Cash Add-back) | 8.06M | 5.29M | 6.75M | 6.88M | 5.72M | 3.42M | 2.94M |
| EBIT | -20.63M | -19.31M | -18.96M | -8.62M | -19.44M | -7.63M | -13.76M |
| Net Interest Income | 0 | -13.84M | -3.05M | -368.66K | -581.82K | -20.83K | -189.14K |
| Interest Income | 11.86M | 0 | 0 | 0 | 14.19K | 515.31K | 371.77K |
| Interest Expense | 0 | 13.84M | 3.05M | 368.66K | 596.02K | 536.14K | 560.91K |
| Other Income/Expense | -24.84M | -13.84M | -4.73M | 9.06M | -121.82K | 5.45M | 3.36M |
| Pretax Income | -32.49M | -33.16M | -22.01M | -8.99M | -20.04M | -8.16M | -14.32M |
| Pretax Margin % | -2.31% | -2.13% | -2.3% | -1.15% | -3.34% | -1.4% | -2.8% |
| Income Tax | -13.37K | -645.87K | -1.43M | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 0.98% | 0.94% | 1% | 1% | 1% | 1% |
| Net Income | -32.47M | -32.51M | -20.59M | -8.99M | -20.04M | -8.16M | -14.32M |
| Net Margin % | -2.31% | -2.09% | -2.15% | -1.15% | -3.34% | -1.4% | -2.8% |
| Net Income Growth % | - | -0% | 0.37% | 0.56% | -1.23% | 0.59% | -0.75% |
| Net Income (Continuing) | -32.47M | -32.51M | -20.59M | -8.99M | -20.04M | -8.16M | -14.32M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -324.73 | -132.16 | -38.55 | -8.25 | -9.68 | -6.35 | -3.34 |
| EPS Growth % | - | 0.59% | 0.71% | 0.79% | -0.17% | 0.34% | 0.47% |
| EPS (Basic) | -324.73 | -132.16 | -38.55 | -8.25 | -9.68 | -6.35 | -3.34 |
| Diluted Shares Outstanding | 100K | 246K | 534.07K | 1.09M | 2.07M | 2.18M | 8.03M |
| Basic Shares Outstanding | 100K | 246K | 534.07K | 1.09M | 2.07M | 1.29M | 8.03M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.81M | 12.09M | 25.91M | 30.54M | 14.67M | 20.39M | 7.29M |
| Cash & Short-Term Investments | 2.79M | 2.15M | 17.14M | 23.85M | 9.43M | 13.34M | 3.71M |
| Cash Only | 2.79M | 2.15M | 17.14M | 23.85M | 9.43M | 13.34M | 3.71M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.51M | 3.85M | 5.15M | 3.06M | 2.11M | 2.23M | 416.08K |
| Days Sales Outstanding | 91.23 | 90.17 | 196.75 | 143.19 | 128.54 | 139.56 | 29.71 |
| Inventory | 6.49M | 2.2M | 760.53K | 519.65K | 1.82M | 1.61M | 3M |
| Days Inventory Outstanding | 226.03 | 63.26 | 68.6 | 118.58 | 289.38 | 360.34 | 902.65 |
| Other Current Assets | 1.64M | 1.94M | 1.48M | 1.53M | 802.21K | 816.21K | 6.53K |
| Total Non-Current Assets | 51.08M | 46.28M | 43.95M | 36.85M | 17.75M | 13.41M | 3.34M |
| Property, Plant & Equipment | 0 | 69.84K | 643.78K | 524.95K | 397.65K | 255.22K | 136.68K |
| Fixed Asset Turnover | - | 223.05x | 14.85x | 14.88x | 15.07x | 22.81x | 37.40x |
| Goodwill | 2.44M | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 44.1M | 38.81M | 32.16M | 25.29M | 12.24M | 8.97M | 3.2M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 4.53M | 7.4M | 11.14M | 11.03M | 5.11M | 4.18M | 0 |
| Total Assets | 66.89M | 58.37M | 69.85M | 67.39M | 32.42M | 33.8M | 10.64M |
| Asset Turnover | 0.21x | 0.27x | 0.14x | 0.12x | 0.18x | 0.17x | 0.48x |
| Asset Growth % | - | -0.13% | 0.2% | -0.04% | -0.52% | 0.04% | -0.69% |
| Total Current Liabilities | 38.54M | 41.1M | 41.89M | 30.98M | 7.07M | 10.77M | 18.03M |
| Accounts Payable | 1.75M | 3.78M | 5.61M | 4.56M | 1.81M | 1.71M | 2.33M |
| Days Payables Outstanding | 61.02 | 108.38 | 505.99 | 1.04K | 287.99 | 383.36 | 700.97 |
| Short-Term Debt | 19.3M | 6.68M | 7.18M | 0 | 1.09M | 1.16M | 7.25M |
| Deferred Revenue (Current) | 0 | 0 | 0 | -125.58K | 0 | 1000K | 0 |
| Other Current Liabilities | 12.57M | 453.09K | 26.04M | 22.93M | 822.39K | 1.11M | 7.1M |
| Current Ratio | 0.41x | 0.29x | 0.62x | 0.99x | 2.08x | 1.89x | 0.40x |
| Quick Ratio | 0.24x | 0.24x | 0.60x | 0.97x | 1.82x | 1.74x | 0.24x |
| Cash Conversion Cycle | 256.24 | 45.06 | -240.64 | -778.3 | 129.93 | 116.54 | 231.38 |
| Total Non-Current Liabilities | 30.03M | 9.24M | 10.49M | 865.02K | 8.65M | 10.55M | 75.22K |
| Long-Term Debt | 27.89M | 7.06M | 0 | 0 | 8.39M | 6.86M | 0 |
| Capital Lease Obligations | 0 | 0 | 530.6K | 405.02K | 262.68K | 137.66K | 75.22K |
| Deferred Tax Liabilities | 2.08M | 1.43M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 57.4K | 749.55K | 9.96M | 460K | 0 | 3.55M | 0 |
| Total Liabilities | 68.57M | 50.35M | 52.38M | 31.85M | 15.72M | 21.32M | 18.1M |
| Total Debt | 47.19M | 13.74M | 7.81M | 405.02K | 9.88M | 8.28M | 7.39M |
| Net Debt | 44.4M | 11.6M | -9.33M | -23.44M | 456.53K | -5.06M | 3.68M |
| Debt / Equity | - | 1.71x | 0.45x | 0.01x | 0.59x | 0.66x | - |
| Debt / EBITDA | 113.79x | - | - | - | - | - | - |
| Net Debt / EBITDA | 107.05x | - | - | - | - | - | - |
| Interest Coverage | - | -1.39x | -5.66x | -48.96x | -33.41x | -25.40x | -31.52x |
| Total Equity | -1.68M | 8.02M | 17.47M | 35.54M | 16.7M | 12.48M | -7.47M |
| Equity Growth % | - | 5.77% | 1.18% | 1.03% | -0.53% | -0.25% | -1.6% |
| Book Value per Share | -16.81 | 32.60 | 32.71 | 32.64 | 8.07 | 5.74 | -0.93 |
| Total Shareholders' Equity | -1.68M | 8.02M | 17.47M | 35.54M | 16.7M | 12.48M | -7.47M |
| Common Stock | 0 | 29.12M | 971 | 2.07K | 208 | 298 | 1.05K |
| Retained Earnings | -1.68M | -41.12M | -61.7M | -70.69M | -90.73M | -98.89M | -113.21M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 8.02M | 2.53M | -15.31M | -11.86M | -12.8M | -7.63M | -2.6M |
| Operating CF Margin % | 0.57% | 0.16% | -1.6% | -1.52% | -2.14% | -1.31% | -0.51% |
| Operating CF Growth % | - | -0.68% | -7.04% | 0.22% | -0.08% | 0.4% | 0.66% |
| Net Income | -32.47M | -32.51M | -20.59M | -8.99M | -20.04M | -8.16M | -14.32M |
| Depreciation & Amortization | 8.06M | 5.29M | 6.66M | 6.88M | 5.72M | 3.42M | 2.94M |
| Stock-Based Compensation | 0 | 0 | 0 | 1.31M | 1.2M | 417.23K | 197.22K |
| Deferred Taxes | -6.94K | -645.87K | -1.43M | -9.48M | 0 | 0 | 0 |
| Other Non-Cash Items | 42.55M | 17.3M | 5.65M | 186.82K | 3.63M | -3.92M | 4.05M |
| Working Capital Changes | 4.93M | 13.09M | -5.6M | -1.76M | -3.3M | 624.91K | 4.53M |
| Change in Receivables | 1.95M | 932.89K | -2.75M | 2.55M | 515.96K | -144.13K | 1.82M |
| Change in Inventory | 96.58K | 2.56M | 728.29K | 412.74K | -835.32K | 273.61K | 307.59K |
| Change in Payables | -965.04K | 2.02M | 2.22M | -1.05M | -2.75M | -93.15K | 615.68K |
| Cash from Investing | -1.88M | -71.54K | -4.63K | 0 | 0 | 0 | -24.59K |
| Capital Expenditures | -1.88M | -71.54K | -4.63K | 0 | 0 | 0 | -24.59K |
| CapEx % of Revenue | 0.13% | 0% | 0% | - | - | - | 0% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -2.55M | -3.11M | 30.3M | 18.57M | -1.62M | 11.54M | -7M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -1.29B |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 21.52M | 4.01M | 0 | 15M | 1.29B |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | 6.15M | 2.46M | -15.31M | -11.86M | -12.8M | -7.63M | -2.63M |
| FCF Margin % | 0.44% | 0.16% | -1.6% | -1.52% | -2.14% | -1.31% | -0.51% |
| FCF Growth % | - | -0.6% | -7.22% | 0.23% | -0.08% | 0.4% | 0.66% |
| FCF per Share | 61.45 | 10.00 | -28.67 | -10.89 | -6.18 | -3.50 | -0.33 |
| FCF Conversion (FCF/Net Income) | -0.25x | -0.08x | 0.74x | 1.32x | 0.64x | 0.93x | 0.18x |
| Interest Paid | 0 | 2.04M | 1.19M | 0 | 596.02K | 536.14K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -1025.92% | -161.53% | -33.9% | -76.7% | -55.95% | -571.33% |
| Return on Invested Capital (ROIC) | -13.43% | -46.47% | -93.38% | -133.71% | -102.09% | -83.1% | -730.89% |
| Gross Margin | 25.41% | 18.35% | 57.67% | 79.52% | 61.79% | 71.98% | 76.28% |
| Net Margin | -231.1% | -208.71% | -215.35% | -115.05% | -334.4% | -140.2% | -280.1% |
| Debt / Equity | - | 1.71x | 0.45x | 0.01x | 0.59x | 0.66x | - |
| Interest Coverage | - | -1.39x | -5.66x | -48.96x | -33.41x | -25.40x | -31.52x |
| FCF Conversion | -0.25x | -0.08x | 0.74x | 1.32x | 0.64x | 0.93x | 0.18x |
| Revenue Growth | - | 10.86% | -38.63% | -18.29% | -23.29% | -2.83% | -12.2% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Medical Devices | - | - | 3.54M | 3.15M |
| Medical Devices Growth | - | - | - | -10.90% |
| Medical Device Sales | 3.21M | 3.26M | - | - |
| Medical Device Sales Growth | - | 1.60% | - | - |
| Prescription Medication Sales | 4.61M | - | - | - |
| Prescription Medication Sales Growth | - | - | - | - |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| UNITED STATES | - | - | - | 4.04M |
| UNITED STATES Growth | - | - | - | - |
| Non-US | - | - | - | 1.07M |
| Non-US Growth | - | - | - | - |
| United States | 6.57M | 4.8M | 4.53M | - |
| United States Growth | - | -26.99% | -5.68% | - |
| International | - | - | 1.3M | - |
| International Growth | - | - | - | - |
| Non Us | - | 1.19M | - | - |
| Non Us Growth | - | - | - | - |
Petros Pharmaceuticals, Inc. (PTPI) reported $0.7M in revenue for fiscal year 2024. This represents a 95% decrease from $14.1M in 2018.
Petros Pharmaceuticals, Inc. (PTPI) saw revenue decline by 12.2% over the past year.
Petros Pharmaceuticals, Inc. (PTPI) reported a net loss of $7.0M for fiscal year 2024.
Yes, Petros Pharmaceuticals, Inc. (PTPI) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Petros Pharmaceuticals, Inc. (PTPI) has a return on equity (ROE) of -571.3%. Negative ROE indicates the company is unprofitable.
Petros Pharmaceuticals, Inc. (PTPI) had negative free cash flow of $4.8M in fiscal year 2024, likely due to heavy capital investments.